Market Overview

UPDATE: Cantor Fitzgerald Initiates Coverage on Bruker

Share:
Related BRKR
Earnings Scheduled For February 13, 2017
Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector

According to a research report published Thursday, Cantor Fitzgerald has initiated Bruker (NASDAQ: BRKR) with a Buy rating and $16 PT.

In the report, Cantor Fitzgerald said, "Bruker has a highly diversified high-end scientific instrumentation portfolio targeting life science, applied, and industrial markets. In our view, the company is well positioned to capitalize on high-growth market segments over the next several years and deliver above-market top line growth, leveraging internal R&D and strategic tuckins. Additionally, with below sector average margins, Bruker has significant upside for margin expansion in the medium-term."

Bruker closed Wednesday at $13.39.

Latest Ratings for BRKR

DateFirmActionFromTo
Jan 2017Deutsche BankInitiates Coverage OnHold
Jan 2017BarclaysDowngradesOverweightEqual-Weight
Dec 2016JP MorganDowngradesNeutralUnderweight

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Analyst Ratings

 

Related Articles (BRKR)

View Comments and Join the Discussion!